×
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
NASDAQ:ANAB

AnaptysBio Stock Forecast, Price & News

$21.97
-0.55 (-2.44%)
(As of 06/28/2022 11:16 AM ET)
Add
Compare
Today's Range
$21.96
$22.57
50-Day Range
$18.71
$24.47
52-Week Range
$18.20
$37.89
Volume
439 shs
Average Volume
345,758 shs
Market Capitalization
$619.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50
30 days | 90 days | 365 days | Advanced Chart

Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Stock Forecast (MarketRank)

Overall MarketRank

2.33 out of 5 stars

Medical Sector

247th out of 1,436 stocks

Pharmaceutical Preparations Industry

98th out of 687 stocks

Analyst Opinion: 3.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
AnaptysBio logo

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB Stock News Headlines

AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $19.82
AnaptysBio (NASDAQ:ANAB) Trading Up 4.8%
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANAB
Fax
N/A
Employees
102
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
6/28/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$39.50
High Stock Price Forecast
$46.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+79.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
3 Analysts

Profitability

Net Income
$-57.80 million
Net Margins
-143.46%
Pretax Margin
-143.46%

Debt

Sales & Book Value

Annual Sales
$63.17 million
Book Value
$12.89 per share

Miscellaneous

Free Float
18,349,000
Market Cap
$619.33 million
Optionable
Optionable
Beta
0.19














AnaptysBio Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AnaptysBio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View analyst ratings for AnaptysBio
or view top-rated stocks.

What is AnaptysBio's stock price forecast for 2022?

3 brokerages have issued 12-month price objectives for AnaptysBio's shares. Their ANAB stock forecasts range from $33.00 to $46.00. On average, they predict AnaptysBio's share price to reach $39.50 in the next twelve months. This suggests a possible upside of 79.8% from the stock's current price.
View analysts' price targets for AnaptysBio
or view top-rated stocks among Wall Street analysts.

How has AnaptysBio's stock performed in 2022?

AnaptysBio's stock was trading at $34.75 at the beginning of 2022. Since then, ANAB stock has decreased by 36.8% and is now trading at $21.97.
View the best growth stocks for 2022 here
.

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for AnaptysBio
.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) posted its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by $0.44. The biotechnology company had revenue of $0.97 million for the quarter, compared to analyst estimates of $8.08 million. AnaptysBio had a negative net margin of 143.46% and a negative trailing twelve-month return on equity of 20.44%.
View AnaptysBio's earnings history
.

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:
  • Mr. Daniel R. Faga, Interim Pres & CEO and Director (Age 42, Pay $3.91k)
  • Mr. Eric J. Loumeau, COO & Gen. Counsel (Age 59, Pay $639.88k) (LinkedIn Profile)
  • Mr. Hamza Suria M.B.A., M.Sc., Advisory (Age 46, Pay $836.53k)
  • Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer (Age 47, Pay $683.17k)
  • Mr. Dennis M. Mulroy, Chief Financial Officer (Age 67)
  • Ms. Beth Mueller, Sr. VP of HR
  • Dr. Martin Dahl Ph.D., Sr. VP of Discovery Biology

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.48%), BlackRock Inc. (6.47%), Federated Hermes Inc. (5.69%), State Street Corp (3.40%), Frazier Life Sciences Management L.P. (3.19%) and Dimensional Fund Advisors LP (3.16%). Company insiders that own AnaptysBio stock include Ecor1 Capital, Llc, Eric J Loumeau and Hamza Suria.
View institutional ownership trends for AnaptysBio
.

Which institutional investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Eversept Partners LP, Arrowstreet Capital Limited Partnership, BlackRock Inc., Acadian Asset Management LLC, Citigroup Inc., Los Angeles Capital Management LLC, and Vanguard Group Inc.. Company insiders that have sold AnaptysBio company stock in the last two years include Eric J Loumeau, and Hamza Suria.
View insider buying and selling activity for AnaptysBio
or view top insider-selling stocks.

Which institutional investors are buying AnaptysBio stock?

ANAB stock was acquired by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Deep Track Capital LP, Woodline Partners LP, Great Point Partners LLC, Dimensional Fund Advisors LP, State Street Corp, Rock Springs Capital Management LP, and Bank of America Corp DE.
View insider buying and selling activity for AnaptysBio
or or view top insider-buying stocks.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $21.97.

How much money does AnaptysBio make?

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $619.33 million and generates $63.17 million in revenue each year. The biotechnology company earns $-57.80 million in net income (profit) each year or ($2.75) on an earnings per share basis.

How many employees does AnaptysBio have?

AnaptysBio employs 102 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for AnaptysBio is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at [email protected].

This page (NASDAQ:ANAB) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.